Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response
Ontology highlight
ABSTRACT: Tau (MAPT) is a microtubule-associated protein causing frequent neurodegenerative diseases or inherited frontotemporal lobar degenerations. Emerging evidence for non-canonical functions of Tau in DNA protection and P53 regulation suggests its involvement in cancer. Indeed, Tau expression correlates with cancer-specific survival or response to microtubule therapeutics. These data may imply common molecular pathways involved in the pathogenesis of neurodegenerative disorders and cancer. To bring new evidence that Tau represents a key protein in cancer, we present an in silico pan-cancer analysis of MAPT transcriptomic profile in over 11000 clinical samples and over 1300 pre-clinical samples provided by the TCGA and the DEPMAP datasets respectively. We completed this analysis by exploring a possible interplay of MAPT with wild-type or mutated P53. Then, we calculated the impact of MAPT expression on clinical outcome and drug response. Overall, the results support a relevant role of the MAPT gene in several cancer types, although the contribution of Tau to cancer appears to very much depend on the cellular context.
INSTRUMENT(S): NextSeq 500
ORGANISM(S): Homo sapiens
SUBMITTER:
PROVIDER: E-MTAB-8166 | biostudies-arrayexpress |
SECONDARY ACCESSION(S): ERP116452
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA